Previous 10 | Next 10 |
BERKELEY, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc . (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribou’s President and Chief Executive Officer, will present a com...
Although shares of CRISPR Therapeutics (CRSP -6.4%) have fallen since yesterday's after-the-bell announcement, its gene editing peers have not been impacted. Those results were from the company’s early-stage trial of its CAR-T cell therapy CTX110. Autolus Therapeutics (AUTL +...
Caribou, founded by Jennifer Doudna, uses a different editing tool. However, its stock has fallen considerably since Allogene's clinical hold. The market probably thinks that even if the tool is different, the effect may be similar. For further details see: Caribou Biosc...
Gainers: ChemoCentryx (NASDAQ:CCXI) +70%. Renren (NYSE:RENN) +48%. DatChat (NASDAQ:DATS) +32%. ReShape Lifesciences (NASDAQ:RSLS) +29%. Huadi International (NASDAQ:HUDI) +24%. Voyager (NASDAQ:VYGR) +22%. NextPlay Technologies (NASDAQ:NXTP) +21%. Tian Ruixiang (NASDAQ:TIRX) +20%. Lilium (NASDA...
The following slide deck was published by Caribou Biosciences, Inc. in conjunction with this event. For further details see: Caribou Biosciences (CRBU) Investor Presentation - Slideshow
Gainers: ChemoCentryx CCXI +57%, ReShape Lifesciences (NASDAQ:RSLS) +30%, Voyager Therapeutics VYGR +13%, Sundial Growers (NASDAQ:SNDL) +10%, Flora Growth (NASDAQ:FLGC) +6%. Losers: Allogene Therapeutics ALLO -42%, Cellectis CLLS -19%,...
Gainers: MNTV +14.5%. AUTL +10.9%. QDEL +7.8%. APM +6.7%. OLED +5.6%. Losers: ALLO -33.5%. CLLS -18.9%. MXCT -16.1%. CDAK -5.8%. CRBU -5.8%. For further details see: MNTV, AUTL, ALLO and CLLS among after hours movers
Gene-editing companies are fighting for their share in a future multi-trillion dollar market. BEAM has a great management team, the best gene-editing technology, and follows a very smart platform licensing approach and is therefore positioned to dominated that market. Investing in...
BERKELEY, Calif., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today it has appointed Ran Zheng to its board of directors. Ms. Zheng brings over 25 years of biotechnology i...
BERKELEY, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribou’s president and chief executive officer, will participate i...
News, Short Squeeze, Breakout and More Instantly...
Caribou Biosciences Inc. Company Name:
CRBU Stock Symbol:
NASDAQ Market:
Caribou Biosciences Inc. Website:
-- Dr. Laufer is an immunologist advancing the scientific understanding and treatment of autoimmune diseases -- BERKELEY, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today a...
2024-06-04 08:30:04 ET H.C. Wainwright analyst issues BUY recommendation for CRBU on June 4, 2024 06:46AM ET. The previous analyst recommendation was Buy. CRBU was trading at $2.145 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...
A look at the top 10 most actives in the United States Crown Electrokinetics Corp. (CRKN) rose 22.3% to $0.12231 on volume of 147,748,197 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 11.8% to $0.6524 on volume of 95,235,738 shares AMC Entertainment Holdings Inc. Class A (AM...